Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland
Smallpox vaccination strategies are evolving rapidly and have important implications for human immunodeficiency virus (HIV)–infected persons. Cell‐mediated immunity is important for controlling both smallpox and vaccinia. For smallpox, the concern is a substantial increase in the associated mortality rate, which is 30% among healthy persons. For smallpox vaccination, the concern is progressive vaccinia, which is usually lethal but relatively uncommon. The risks associated with both smallpox and vaccinia viruses probably correlate with CD4 cell count, and, as a corollary, the best protection against infection with each is presumably immune reconstitution. It appears that all vaccinations will be voluntary, with 2 recommendations: (1) HIV‐infected persons will be advised to decline preemptive vaccination, and (2) in the event of a bioterrorism attack involving smallpox, HIV‐infected patients with exposures will be advised to receive vaccine.
Cited by
John Neff, John Modlin, Guthrie S. Birkhead, Gregory Poland, Rose Marie Robertson, Kent Sepkowitz, Clyde Yancy, Pierce Gardner, Gregory C. Gray, Toby Maurer, Jane Siegel, Fernando A. Guerra, Tim Berger, W. Dana Flanders, and Robert Shope. (2008) Monitoring the Safety of a Smallpox Vaccination Program in the United States: Report of the Joint Smallpox Vaccine Safety Working Group of the Advisory Committee on Immunization Practices and the Armed Forces Epidemiological Board.
Clinical Infectious Diseases 46:s3, S258-S270
Online publication date: 15-Mar-2008.
Antonio Cosma, Rashmi Nagaraj, Caroline Staib, Claudia Diemer, Franziska Wopfner, Hermann Schätzl, Dirk H. Busch, Gerd Sutter, Frank D. Goebel, Volker Erfle. (2007) Evaluation of Modified Vaccinia Virus Ankara as an Alternative Vaccine against Smallpox in Chronically HIV Type 1-Infected Individuals Undergoing HAART.
AIDS Research and Human Retroviruses 23:6, 782-793
Online publication date: 1-Jul-2007.
CrossRef Virginia L Kan, Jody Manischewitz, Lisa R King, Hana Golding. (2007) Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.
AIDS 21:4, 521???524
Online publication date: 1-Mar-2007.
CrossRef Ian J. Amanna, Mark K. Slifka, Shane Crotty. (2006) Immunity and immunological memory following smallpox vaccination.
Immunological Reviews 211:1, 320-337
Online publication date: 1-Jul-2006.
CrossRef Robert J. Hopkins and J. Michael Lane. (2004) Clinical Efficacy of Intramuscular Vaccinia Immune Globulin: A Literature Review.
Clinical Infectious Diseases 39:6, 819-826
Online publication date: 15-Sep-2004.
Sybil A. Tasker, Glenn A. Schnepf, Matthew Lim, Harold E. Caraviello, Adam Armstrong, Mary Bavaro, Brian K. Agan, Judith Delmar, Naomi Aronson, Mark R. Wallace, and John D. Grabenstein, for the US Department of Defense Tri‐Service AIDS Clinical Consortium. (2004) Unintended Smallpox Vaccination of HIV‐1–Infected Individuals in the United States Military.
Clinical Infectious Diseases 38:9, 1320-1322
Online publication date: 1-May-2004.
Valerianna K. Amorosa and Stuart N. Isaacs. (2003) Separate Worlds Set to Collide: Smallpox, Vaccinia Virus Vaccination, and Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome.
Clinical Infectious Diseases 37:3, 426-432
Online publication date: 1-Aug-2003.
Vincent A. Fulginiti, Arthur Papier, J. Michael Lane, John M. Neff, and D. A. Henderson. (2003) Smallpox Vaccination: A Review, Part II. Adverse Events.
Clinical Infectious Diseases 37:2, 251-271
Online publication date: 15-Jul-2003.
Vincent A. Fulginiti, Arthur Papier, J. Michael Lane, John M. Neff, and D. A. Henderson. (2003) Smallpox Vaccination: A Review, Part I. Background, Vaccination Technique, Normal Vaccination and Revaccination, and Expected Normal Reactions.
Clinical Infectious Diseases 37:2, 241-250
Online publication date: 15-Jul-2003.